Clinical Trial: Evaluation of 200 Mg of Rituximab Every 6 Months As Maintenance Treatment of Rituximab-treated Patients with Rheumatoid Arthritis

U.S., April 3 -- ClinicalTrials.gov registry received information related to the study (NCT06906549) titled 'Evaluation of 200 Mg of Rituximab Every 6 Months As Maintenance Treatment of Rituximab-treated Patients with Rheumatoid Arthritis' on March 18.

Brief Summary: Rheumatoid arthritis (RA) is a chronic inflammatory disease affecting joints and causing progressive disability. Current treatment strategies involve conventional disease-modifying anti-rheumatic drugs (csDMARDs) and, in more resistant cases, biologic DMARDs (bDMARDs) such as Rituximab. Rituximab, a monoclonal antibody targeting CD20-positive B cells, is administered as an induction dose followed by maintenance therapy every six months. Standard maintenance dosing consists of ...